November 29, 2021 -- Codex DNA has launched its BioXp mRNA synthesis kits with CleanCap Reagent, a proprietary mRNA-capping technology from TriLink Biotechnologies, which is part of Maravai Life Sciences. The automation kits allow users to generate large quantities of high-quality, capped mRNA to accelerate the discovery and development of mRNA vaccines and therapeutics.
The kits are designed to increase the productivity and efficacy of mRNA synthesis workflows. Codex Users can generate up to 16 biologically active mRNA constructs at a median yield of 10 mcg each from fully de novo synthesized and error-corrected genes in a single automated run. This simplifies and shortens the mRNA manufacturing process for increased protein production, according to the firm.
TriLink Biotechnologies is a contract development and manufacturing organization with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap mRNA-capping technology. Codex DNA provides synthetic biology-enabled solutions and has previously launched a commercial automated benchtop DNA and mRNA synthesis system.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
